Background: GH therapy response varies substantially among patients. Several models were developed to predict the efficacy of GH therapy in children. Aim: To evaluate the accuracy of a growth prediction model using data from an Italian pediatric GH deficiency (GHD) cohort (GeNeSIS, Growth Prediction Sub-study). Methods: Open-label, multicenter study in 22 Italian pre-pubertal GH treatment-naive patients with GHD (8 female, 14 male, 0.5 to 12.2 yr), 18 isolated GHD, 4 multiple pituitary hormone deficiency given recombinat human GH therapy (0.025-0.035 mg/kg/day) for 12 months. Growth prediction was performed, after 3 months of treatment, using baseline data [bone age (BA) and IGF-I), a urinary marker of bone turnover [deoxypyridinoline crosslinks (DPD)) at 4 weeks, and height velocity (HV) at 3 months. Results were expressed as 1(st)-yr HV using the following equation: 1-yr HV (cm) = 3.543 - (2.337 x BA) - (0.010 x IGF-I) + (0.100 x DPD) + (0.299 x 3-month HV). Predictions were compared to the 1(st)-yr NV and accuracy was calculated as percentage of the difference between mean calculated NV and the real 1(st)-yr NV. Results: For females predicted HV was 12.98 +/- 4.82 cm/yr and actually was 13.05 +/- 3.91 cm/yr after the 1(st) year; for males predicted NV was 13.95 +/- 5.39 cm/yr and actually was 12.93 +/- 5.02 cm/yr. Conclusions: In this paediatric Italian cohort with GHD, a growth prediction model seems to be a valid tool to assess 1(st)-yr response to GH treatment in Italian children. (J. Endocrinol. Invest. 34: e126-e130, 2011) (C) 2011, Editrice Kurtis
Prediction of response to growth hormone treatment in pre-pubertal children with growth hormone deficiency
SAGGESE, GIUSEPPE;
2011-01-01
Abstract
Background: GH therapy response varies substantially among patients. Several models were developed to predict the efficacy of GH therapy in children. Aim: To evaluate the accuracy of a growth prediction model using data from an Italian pediatric GH deficiency (GHD) cohort (GeNeSIS, Growth Prediction Sub-study). Methods: Open-label, multicenter study in 22 Italian pre-pubertal GH treatment-naive patients with GHD (8 female, 14 male, 0.5 to 12.2 yr), 18 isolated GHD, 4 multiple pituitary hormone deficiency given recombinat human GH therapy (0.025-0.035 mg/kg/day) for 12 months. Growth prediction was performed, after 3 months of treatment, using baseline data [bone age (BA) and IGF-I), a urinary marker of bone turnover [deoxypyridinoline crosslinks (DPD)) at 4 weeks, and height velocity (HV) at 3 months. Results were expressed as 1(st)-yr HV using the following equation: 1-yr HV (cm) = 3.543 - (2.337 x BA) - (0.010 x IGF-I) + (0.100 x DPD) + (0.299 x 3-month HV). Predictions were compared to the 1(st)-yr NV and accuracy was calculated as percentage of the difference between mean calculated NV and the real 1(st)-yr NV. Results: For females predicted HV was 12.98 +/- 4.82 cm/yr and actually was 13.05 +/- 3.91 cm/yr after the 1(st) year; for males predicted NV was 13.95 +/- 5.39 cm/yr and actually was 12.93 +/- 5.02 cm/yr. Conclusions: In this paediatric Italian cohort with GHD, a growth prediction model seems to be a valid tool to assess 1(st)-yr response to GH treatment in Italian children. (J. Endocrinol. Invest. 34: e126-e130, 2011) (C) 2011, Editrice KurtisI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
